PE52396A1 - Nuevo compuesto que puede mantener, aumentar o restaurar la sensibilidad de las celulas a los agentes terapeuticos o profilacticos - Google Patents

Nuevo compuesto que puede mantener, aumentar o restaurar la sensibilidad de las celulas a los agentes terapeuticos o profilacticos

Info

Publication number
PE52396A1
PE52396A1 PE1995284732A PE28473295A PE52396A1 PE 52396 A1 PE52396 A1 PE 52396A1 PE 1995284732 A PE1995284732 A PE 1995284732A PE 28473295 A PE28473295 A PE 28473295A PE 52396 A1 PE52396 A1 PE 52396A1
Authority
PE
Peru
Prior art keywords
formula
straight
branched
rent
replaced
Prior art date
Application number
PE1995284732A
Other languages
English (en)
Inventor
Robert E Zelle
Matthew W Harding
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PE52396A1 publication Critical patent/PE52396A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE AL COMPUESTO USADO EN EL TRATAMIENTO DE LAS CELULAS RESISTENTES A MULTIDROGAS, DE FORMULA I DONDE: R1, B y D SON INDEPENDIENTEMENTE Ar, ALQUILO RECTO O RAMIFICADO DE (C1-C6), ALQUENILO RECTO O RAMIFICADO DE (C2-C6) ENTRE OTROS, EN DONDE CUALQUIERA DE LOS GRUPOS CH2 DE DICHAS CADENAS ALQUILO PUEDEN SER REEMPLAZADAS POR UN HETEROATOMO SELECCIONADO DEL GRUPO O, S, SO, SO2 Y NR; B Y D TAMBIEN PUEDEN SER HIDROGENO, SIEMPRE QUE R1 NO SEA NITROGENO; J ES ALQUILO RECTO O RAMIFICADO DE (C1-C6), ALQUENILO RECTO O RAMIFICADO DE (C3-C6) ENTRE OTROS; K SE SELECCIONA DEL GRUPO CONSISTENTE DE ALQUILO RECTO DE (C1-C6) O ALQUILO RAMIFICADO (C1-C6), Ar SUSTITUIDO RECTO O RAMIFICADO (C1-C6), Ar SUSTITUIDO ALQUENILO RECTO O RAMIFICADO DE (C2-C6) ENTRE OTROS; X SE SELECCIONA DE Ar, -OR2, NR3R4, EN DONDE R2 TIENE LA MISMA DEFINICION DE R1 y, R3 Y R4 TIENEN LAS MISMAS DEFINICIONES DE B Y D, Y R3 Y R4 JUNTOS FORMAN UN ANILLO HETEROCICLICO ALIFATICO O AROMATICO DE 5 A 7 MIEMBROS; m ES 0 o 1; TAMBIEN SE REFIERE AL PROCESO DE SINTESIS DEL COMPUESTO DE FORMULA I QUE COMPRENDE: a) ACOPLAR UN AMINOACIDO DE FORMULA IV CON UNA AMINA DE FORMULA V, PARA DAR UNA AMIDA DE FORMULA VI; b) DESPROTEGER LA AMIDA DE FORMULA VI PARA DAR UNA AMINO AMIDA DE FORMULA VII; c) ACILAR LA AMINO AMIDA DE FORMULA VII CON EL COMPUESTO DE FORMULA VIII
PE1995284732A 1994-11-16 1995-11-16 Nuevo compuesto que puede mantener, aumentar o restaurar la sensibilidad de las celulas a los agentes terapeuticos o profilacticos PE52396A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34083094A 1994-11-16 1994-11-16
US08/377,285 US5543423A (en) 1994-11-16 1995-01-23 Amino acid derivatives with improved multi-drug resistance activity

Publications (1)

Publication Number Publication Date
PE52396A1 true PE52396A1 (es) 1996-12-12

Family

ID=23335106

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995284732A PE52396A1 (es) 1994-11-16 1995-11-16 Nuevo compuesto que puede mantener, aumentar o restaurar la sensibilidad de las celulas a los agentes terapeuticos o profilacticos

Country Status (8)

Country Link
US (1) US5543423A (es)
EP (1) EP1420009A3 (es)
KR (1) KR100404717B1 (es)
CN (1) CN1099407C (es)
AR (1) AR004655A1 (es)
PE (1) PE52396A1 (es)
RU (1) RU2165410C2 (es)
ZA (1) ZA959304B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846981A (en) * 1993-05-28 1998-12-08 Gpi Nil Holdings Inc. Inhibitors of rotamase enzyme activity
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US7056935B2 (en) * 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5804578A (en) * 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US6093816A (en) * 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US6218424B1 (en) 1996-09-25 2001-04-17 Gpi Nil Holdings, Inc. Heterocyclic ketone and thioester compounds and uses
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5846979A (en) 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6162616A (en) * 1997-04-16 2000-12-19 Millennium Pharmaceuticals, Inc. Multidrug resistance-associated polypeptide
US20010049381A1 (en) * 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6187784B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
US6274602B1 (en) 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
US5945441A (en) * 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6187796B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Sulfone hair growth compositions and uses
US6271244B1 (en) 1998-06-03 2001-08-07 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
US6852496B1 (en) * 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US6268384B1 (en) 1997-08-29 2001-07-31 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
KR20010052503A (ko) 1998-06-03 2001-06-25 다니엘 피. 맥컬럼 Ｎ-헤테로사이클릭 카복실산 또는 카복실산 등입체의ｎ-결합된 설폰아미드
US6429215B1 (en) 1998-06-03 2002-08-06 Gpi Nil Holdings, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6274617B1 (en) 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic ester and amide hair growth compositions and uses
US6172087B1 (en) 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6261693B1 (en) * 1999-05-03 2001-07-17 Guardian Industries Corporation Highly tetrahedral amorphous carbon coating on glass
AU6075400A (en) * 1999-07-06 2001-01-22 Vertex Pharmaceuticals Incorporated N-substituted glycine derivatives
US6734211B1 (en) 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
JP2001031635A (ja) 1999-07-14 2001-02-06 Ajinomoto Co Inc 光学活性ｎ−保護−ｎ−メチル−フェニルアラニン誘導体の製造方法
WO2001010821A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent exocyclic diketo compounds
US6734192B1 (en) 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
JP2003518122A (ja) 1999-12-21 2003-06-03 ジーピーアイ エヌアイエル ホールディングズ インコーポレーテッド ヒダントイン誘導体化合物、医薬合成品およびこれらの使用方法
US6258526B1 (en) * 2000-01-19 2001-07-10 M.D.R. Test Ltd Ex-vivo test kit for testing the effectiveness of reversers of multidrug resistance
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
CA2449019A1 (en) * 2001-05-29 2002-12-05 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
AU2002363523A1 (en) * 2001-11-07 2003-05-19 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
WO2005007162A1 (en) * 2003-07-10 2005-01-27 Vertex Pharmaceuticals Incorporated Compounds augmenting the activity of antibacterial agents
US8058430B2 (en) * 2007-06-29 2011-11-15 Florida Atlantic University Broad of Trustees Biologically active aphrocallistin compounds
CA2772786A1 (en) 2009-09-11 2011-03-17 Vertex Pharmaceuticals Incorporated Compositions of n-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]-n-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]propanamide and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2447587A (en) * 1942-12-18 1948-08-24 Geigy Ag J R Acyl glycine amides
DE2328391A1 (de) * 1972-06-19 1974-01-10 Degussa Trialkoxycinnamoylaminocarbonsaeuren
US4296113A (en) * 1980-01-14 1981-10-20 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of keto substituted proline and pipecolic acid
US4376124A (en) * 1982-03-08 1983-03-08 American Home Products Corporation Method for modulating the immune response with dibenzocycloheptenylidenes
US4579840A (en) * 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
JPS6137764A (ja) * 1984-07-31 1986-02-22 Suntory Ltd 抗プロリルエンドペプチダ−ゼ活性を有する新規生理活性化合物
CN86101850A (zh) * 1985-03-22 1987-02-04 森得克斯(美国)有限公司 N，n′-二烷基胍基二肽的制造方法与用途
US4920218A (en) * 1988-10-12 1990-04-24 Merck & Co., Inc. Novel hydroxide mediated FK-506 rearrangement process
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
JP2691442B2 (ja) * 1989-02-20 1997-12-17 株式会社ヤクルト本社 新規なプロリン誘導体
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
GB2247456A (en) * 1990-09-03 1992-03-04 Fujisawa Pharmaceutical Co Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same
US5250678A (en) * 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
CA2074061A1 (en) * 1991-08-26 1993-02-27 Ivo Monkovic Benzamide multidrug resistance reversing agents
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance

Also Published As

Publication number Publication date
KR970707077A (ko) 1997-12-01
EP1420009A2 (en) 2004-05-19
US5543423A (en) 1996-08-06
AR004655A1 (es) 1999-03-10
ZA959304B (en) 1996-05-29
CN1099407C (zh) 2003-01-22
CN1163605A (zh) 1997-10-29
RU2165410C2 (ru) 2001-04-20
KR100404717B1 (ko) 2004-03-30
EP1420009A3 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
PE52396A1 (es) Nuevo compuesto que puede mantener, aumentar o restaurar la sensibilidad de las celulas a los agentes terapeuticos o profilacticos
FI954105A (fi) Uusia 4-aminopyridiinejä, niiden valmistusmenetelmä sekä näitä yhdisteitä sisältäviä lääkkeitä
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
PE51097A1 (es) Nuevos taxoides, su preparacion y composiciones farmaceuticas que los contienen
AR017111A1 (es) Composiciones detergentes para el lavado de ropa con polimeros a base de aminas lineales para proporcionar beneficios en cuanto a aspecto exterior eintegridad a las telas lavadas con las mismas
ES2095942T3 (es) Derivados de bencenoacetamida inhibidores del vih.
UY25211A1 (es) Inhibidores de isoquinolinilguanidina uroquinasa
ES2059688T3 (es) Derivados de aminoacidos inhibidores de enzimas, procedimiento para su preparacion, agentes que los contienen y su utilizacion.
HUP0203275A2 (hu) 1-(Gyűrűs amino)-alkilciklohexán-származékok, ezeket tartalmazó görcsoldó hatású gyógyszerkészítmények, valamint ezek alkalmazása
IE44765L (en) N-substituted benzamides.
ES2060123T3 (es) Aminoacidos protegidos y procedimientos para su fabricacion.
ATE31414T1 (de) 8-substituierte pyrrolizidin-derivate und deren verwendung.
PE20000943A1 (es) Derivados de sulfonamida
ES440107A1 (es) Procedimiento para preparar diaminonaftalenos.
MX173323B (es) Procedimiento para preparar colorantes triazoicos negros y producto obtenido
ES2155546T3 (es) Bencenosulfonil-ureas y -tioureas sustituidas, procedimiento para su preparacion y el uso de preparaciones farmaceuticas basadas en estos compuestos, asi como medicamentos que los contienen.
DE69316392D1 (de) Azanoradamantane
JPS5331618A (en) Novel amino amide compounds, their preparation and surface-active agents containing the same
SE323078B (es)
ES2071177T3 (es) Derivados substituidos de amidas de aminoacido, su obtencion y empleo.
GB1170777A (en) Aminoalkyl Esters, their Acid Addition Salts Isocyanato and Isothiocyanato Derivatives
ES478786A1 (es) Procedimiento para la obtencion de pigmentos de azometina.
DE69414117D1 (de) 1,5-benzodiazepin-derivate verwendbar als cck oder gastrin antagonisten
AR003364A1 (es) Indolinoespiroxacinas y fotocromaticas, composicion y matriz de copolimero que las comprenden y articulos que las contienen.
ES2136667T3 (es) Compuestos de etinil-alanina-amino-diol que tienen un grupo terminado en piperazinilo o un grupo terminado en piperazinil-alquilamino para el tratamiento de la hipertension.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed